Patent US4897254A successfully refreshed from Google Patents.
US4897254A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Radioactive compositions for the treatment of calcific tumors
Assignee: Dow Chemical Co
•
Filing: 1987-03-03
•
Granted: 1990-01-30
•
Expires: 2007-03-03
Abstract
Abstract Certain particle-emitting radionuclides, e.g. Samarium-153, have been complexed with certain alkylenepolyaminocarboxylic acid chelants. Compositions containing these complexes have been found useful in the treatment of calcific tumors in animals. The stability constant, log K, of the useful complexes is from about 14 to about 17 and the molar ratio of chelant to radionuclide in the compositions is such that the chelant is present in an amount sufficient to inhibit uptake of the radionuclide by soft tissue.
Inventors
- 👤 Jaime Simon
- 👤 Wynn A. Volkert
- 👤 David A. Wilson
- 👤 David E. Troutner
- 👤 William F. Goeckeler
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 16:05
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0474; A61K51/0478; A61K2121/00
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
56 words
A composition comprising a complex which comprises a chelant and a radionuclide wherein the chelant is hydroxyethylethylenediaminetriacetic acid or a physiologically acceptable salt thereof with a radionuclide selected from the group consisting of Sm-153, Gd-159 and Ho-166, wherein the molar ratio of chelant to radionuclide is about 50:1 or more, and a physiologically acceptable liquid carrier.
Claim 2
Dependent Claim
56 words
A composition comprising a complex which comprises a chelant and a radionuclide wherein the chelant is hydroxyethylethylenediaminetriacetic acid or a physiologically acceptable salt thereof with a radionuclide selected from the group consisting of Sm-153, Gd-159 and Ho-166, wherein the molar ratio of chelant to radionuclide is about 50:1 or more, and a physiologically acceptable liquid carrier.
Claim 3
Dependent Claim
13 words
The composition of claim 1 wherein the complex is hydroxyethylethylenediaminetriacetic acid with Sm-153.
Claim 4
Dependent Claim
13 words
The composition of claim 1 wherein the complex is hydroxyethylethylenediaminetriacetic acid with Gd-159.
Claim 5
Dependent Claim
13 words
The composition of claim 1 wherein the complex is hydroxyethylethylenediaminetriacetic acid with Ho-166.
Claim 6
Dependent Claim
20 words
The composition of claim 1 wherein the chelant is at least partially in the form of its physiologically acceptable salt.
Claim 7
Dependent Claim
25 words
The composition of claim 5 wherein the physiologically acceptable salt is at least partially in the form of its alkali or alkaline earth metal salt.
Claim 8
Independent Claim
82 words
A method for the therapeutic treatment of an animal having one or more calcific tumors which comprises administering to said animal a therapeutically effective amount of a composition comprising a complex which comprises a chelant and a radionuclide wherein the chelant is hydroxyethylethylenediaminetriacetic acid or a physiologically acceptable salt thereof with a radionuclide selected from the group consisting of Sm-153, Gd-159 and Ho-166, wherein the molar ratio of chelant to radionuclide is about 50:1 or more, and a physiologically acceptable liquid carrier.
Claim 9
Independent Claim
82 words
A method for the therapeutic treatment of an animal having one or more calcific tumors which comprises administering to said animal a therapeutically effective amount of a composition comprising a complex which comprises a chelant and a radionuclide wherein the chelant is hydroxyethylethylenediaminetriacetic acid or a physiologically acceptable salt thereof with a radionuclide selected from the group consisting of Sm-153, Gd-159 and Ho-166, wherein the molar ratio of chelant to radionuclide is about 50:1 or more, and a physiologically acceptable liquid carrier.
Claim 10
Dependent Claim
13 words
The method of claim 7 wherein the complex is hydroxyethylethylenediaminetriacetic acid with Sm-153.
Claim 11
Dependent Claim
13 words
The method of claim 7 wherein the complex is hydroxyethylethylenediaminetriacetic acid with Gd-159.
Claim 12
Dependent Claim
13 words
The method of claim 7 wherein the complex is hydroxyethylethylenediaminetriacetic acid with Ho-166.
Claim 13
Dependent Claim
20 words
The method of claim 7 wherein the chelant is at least partially in the form of its physiologically acceptable salt.
Claim 14
Dependent Claim
25 words
The method of claim 11 wherein the physiologically acceptable salt is at least partially in the form of its alkali or alkaline earth metal salt.
Claim 15
Independent Claim
79 words
A method for the therapeutic treatment of an animal having bone pain which comprises administering to said animal a theerapeutically effective amount of a composition comprising a complex which comprises a chelant and a radionuclide wherein the chelant is hydroxyethylethylenediaminetriacetic acid or a physiologically acceptable salt thereof with a radionuclide selected from the group consisting of Sm-153, Gd-159 and Ho-166, wherein the molar ratio of chelant to radionuclide is about 50:1 or more, and a physiologically acceptable liquid carrier.
Claim 16
Independent Claim
79 words
A method for the therapeutic treatment of an animal having bone pain which comprises administering to said animal a theerapeutically effective amount of a composition comprising a complex which comprises a chelant and a radionuclide wherein the chelant is hydroxyethylethylenediaminetriacetic acid or a physiologically acceptable salt thereof with a radionuclide selected from the group consisting of Sm-153, Gd-159 and Ho-166, wherein the molar ratio of chelant to radionuclide is about 50:1 or more, and a physiologically acceptable liquid carrier.
Claim 17
Dependent Claim
13 words
The method of claim 13 wherein the complex is hydroxyethylethylenediaminetriacetic acid with Sm-153.
Claim 18
Dependent Claim
13 words
The method of claim 13 wherein the complex is hydroxyethylethylenediaminetriacetic acid with Gd-159.
Claim 19
Dependent Claim
13 words
The method of claim 13 wherein the complex is hydroxyethylethylenediaminetriacetic acid with Ho-166.
Claim 20
Dependent Claim
20 words
The method of claim 13 wherein the chelant is at least partially in the form of its physiologically acceptable salt.
Claim 21
Dependent Claim
25 words
The method of claim 17 wherein the physiologically acceptable salt is at least partially in the form of its alkali or alkaline earth metal salt.
References Cited (Backward Citations)
US3965254A
Cited
US4088747A
Cited
US4091088A
Cited
US4017596A
Cited
US4352751A
Cited
US4308249A
Cited
US4399817A
Cited
US4647447A
Cited
EP0083129A1
Cited
US4560548A
Cited
US4606907A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-01-29 | 1993-07-31 | 1994-01-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-01-29 | 1997-07-31 | 1998-01-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-01-29 | 2001-07-31 | 2002-01-30 | $7700.00 | Window Closed / Lapsed |